Gruppen utfører epidemiologiske og kliniske studier med endepunktsdata på pasienter som gjennomgår nyretransplantasjon, pankreastransplantasjon og øycelletransplantasjon.
Data som publiseres er dels registerbasert (via et komplett nasjonalt endepunktsregister som oppdateres årlig (Norsk nyreregister) samt en lokal biobank, dels randomiserte kliniske studier som initieres av gruppen selv, og deltakelse i internasjonale multisenter-studier.
Studiene fokuserer spesielt på immunterapi, farmakokinetikk, farmakokinetisk modellering og metabolisme, sistnevnte med fokus på benmetabolisme etter nyretransplantasjon og på post-transplantasjons diabetes (PTDM).
Gruppen fikk i 2022 innvilget 17.6 mill kroner fra KLINBEFORSK for å starte en placebokontrollert randomisert og blindet intervensjonsstudie med SGLT2-hemmeren dapagliflozin. Hensikten er å finne ut om behandlingen kan forlenge levetiden for den transplanterte nyren.
Prosjekter
- SIMPLIFY study: Simplification of the plasma clearance of iohexol
- Patiromer PK study: Effect of patiromer on pharmacokinetics of immunosuppressive drugs in renal transplant recipients
- Hypomagnesemia as a risk factor for development of posttransplant diabetes mellitus (PhD project Rasmus Kirkeskov Carlsen)
- The microbiome and gut metabolism of mycophenolate acid
- Covid-19 vaccine study among kidney transplant recipients
- EVITA (Epstein-Barr virus infection monitoring in renal transplant recipients)
- BONTRAX – 10 years follow-up of bisphosphonate treatment in kidney transplant recipients
- Home Based Monitoring – patient centric sampling for analyses of tacrolimus, creatinine and hemoglobin
- Post-transplant diabetes mellitus
- Kidney rejection and immunity
- Individualization of immunosuppression, also with home based blood sampling (MitraTip®)
- Biomarkers of outcomes after transplantation
- Measured GFR by iohexol plasma clearance vs. estimated glomerular filtration rate
- Evaluation and follow-up of kidney donors (ALDON Study)
- Long-term effects and safety with human pancreas transplantation.
In relation to these topics altogether 65 peer-reviewed papers were published in international journals in 2022.
Our biobank was expanded, and we have established valid measures for long-term outcome after transplantation (e.g., GFR, pharmacological and metabolic measures, inflammation parameters, etc.).
We have received an EU grant as partner in a twinning project of the Horizon program: Diabetes, Obesity & the Kidney (DOKI).
The research group received a large grant from KLINBEFORSK to start a randomized, blinded and placebo-controlled intervention study on the SGLT2 inhibitor dapagliflozin in kidney transplant recipients. The purpose of the study is to see whether SGLT2 inhibition can prolong the survival time for transplanted kidney grafts.
Samarbeidspartnere
Forskningsgruppen har flere samarbeidspartnere, både nasjonalt og internasjonalt. For mer informasjon, vennligst se vår side på engelsk.
Publikasjoner
- Heldal TF, Åsberg A, Ueland T, Reisæter AV, Pischke SE, Mollnes TE, Aukrust P, Hartmann A, Heldal K, Jenssen T. Inflammation in the early phase after kidney transplantation is associated with increased long-term all-cause mortality. Am J Transplant 2022; 22(8): 2016-2027.
- Tsarpali V, Midtvedt K, Lønning K, Bernklev T, Åsberg A, Fawad H, von der Lippe N, Reisæter AV, Røysland K, Heldal K. A comorbidity index predicts survival in older recipients of deceased donor kidney transplantation; a national prospective study. Transplant Direct 2022; 8(4): e1307.
- Kvitne KE, Robertsen I, Skovlund E, Christensen H, Krogstad V, Wegler C, Angeles PC, Wollmann BM, Hole K, Johnson LK, Sandbu R, Artursson P, Karlsson C, Andersson S, Andersson TB, Hjelmesæth J, Jansson-Löfmark R, Åsberg A. Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed contro 32.
- Haugen AJ, Hallan S, Langberg NE, Dahle DO, Pihlstrøm H, Birkeland KI, Reisæter AV, Midtvedt K, Hartmann A, Holdaas H, Mjøen G. Increased risk of ischaemic heart disease after kidney donation. Nephrol Dial Transplant. 2022; 37(5): 928-936. lled trial. Clin Transl Sci 2022; 15(1): 221-233.
- Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K. Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. Transplantation. 2022; 106(1): e52-e63.